Bicycle Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
Bicycle Therapeutics (NASDAQ: BCYC), a pharmaceutical company specializing in bicyclic peptide (Bicycle®) technology, has announced its upcoming participation in the 24th Annual Needham Virtual Healthcare Conference. The company's management will engage in a fireside chat scheduled for Tuesday, April 8, at 12:45 p.m. ET.
Investors and interested parties can access a live webcast of the presentation through the Investor section of Bicycle Therapeutics' website (www.bicycletherapeutics.com). The company will also make a replay of the webcast available for viewing after the event.
Bicycle Therapeutics (NASDAQ: BCYC), un'azienda farmaceutica specializzata nella tecnologia dei peptidi biciclici (Bicycle®), ha annunciato la sua prossima partecipazione alla 24ª Conferenza Sanitaria Virtuale Annuale di Needham. La direzione dell'azienda parteciperà a una chiacchierata informale programmata per martedì 8 aprile, alle 12:45 ET.
Gli investitori e le parti interessate possono accedere a una diretta streaming della presentazione attraverso la sezione Investor del sito web di Bicycle Therapeutics' (www.bicycletherapeutics.com). L'azienda renderà inoltre disponibile una registrazione della diretta dopo l'evento.
Bicycle Therapeutics (NASDAQ: BCYC), una compañía farmacéutica especializada en la tecnología de péptidos bicíclicos (Bicycle®), ha anunciado su próxima participación en la 24ª Conferencia Virtual Anual de Salud de Needham. La dirección de la compañía participará en una charla informal programada para el martes 8 de abril a las 12:45 p.m. ET.
Los inversionistas y partes interesadas pueden acceder a una transmisión en vivo de la presentación a través de la sección para inversionistas del sitio web de Bicycle Therapeutics' (www.bicycletherapeutics.com). La compañía también hará disponible una grabación de la transmisión después del evento.
바이시클 테라퓨틱스 (NASDAQ: BCYC)는 이중 고리 펩타이드 (Bicycle®) 기술을 전문으로 하는 제약 회사로, 제24회 니드햄 가상 헬스케어 컨퍼런스에 참여할 예정이라고 발표했습니다. 회사 경영진은 4월 8일 화요일 오후 12시 45분 ET에 예정된 대화에 참여할 것입니다.
투자자 및 관심 있는 분들은 Bicycle Therapeutics' 웹사이트의 투자자 섹션을 통해 발표의 실시간 웹캐스트에 접속할 수 있습니다 (www.bicycletherapeutics.com). 회사는 또한 이벤트 후 웹캐스트의 재생을 제공할 예정입니다.
Bicycle Therapeutics (NASDAQ: BCYC), une entreprise pharmaceutique spécialisée dans la technologie des peptides bicycliques (Bicycle®), a annoncé sa prochaine participation à la 24e Conférence Virtuelle Annuelle de Santé de Needham. La direction de l'entreprise participera à une discussion informelle prévue pour le mardi 8 avril à 12h45 ET.
Les investisseurs et les parties intéressées peuvent accéder à un webinaire en direct de la présentation via la section Investisseur du site web de Bicycle Therapeutics' (www.bicycletherapeutics.com). L'entreprise mettra également à disposition un enregistrement du webinaire après l'événement.
Bicycle Therapeutics (NASDAQ: BCYC), ein Pharmaunternehmen, das sich auf bicyclische Peptid (Bicycle®) Technologie spezialisiert hat, hat seine bevorstehende Teilnahme an der 24. jährlichen virtuellen Gesundheitskonferenz von Needham angekündigt. Das Management des Unternehmens wird an einem informellen Gespräch teilnehmen, das für Dienstag, den 8. April, um 12:45 Uhr ET geplant ist.
Investoren und Interessierte können über den Investorenbereich der Website von Bicycle Therapeutics' (www.bicycletherapeutics.com) auf einen Live-Stream der Präsentation zugreifen. Das Unternehmen wird auch eine Wiederholung des Streams nach der Veranstaltung zur Verfügung stellen.
- None.
- None.
A live webcast of the fireside chat will be accessible from the Investor section of the company’s website at www.bicycletherapeutics.com. A replay of the webcast will be archived and available following the event.
About Bicycle Therapeutics
Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating zelenectide pevedotin (formerly BT8009), a Bicycle® Drug Conjugate (BDC™) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BDC molecule targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle® Radioconjugates (BRC®) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology.
Bicycle Therapeutics is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250401471211/en/
Investors:
Stephanie Yao
SVP, Investor Relations and Corporate Communications
stephanie.yao@bicycletx.com
857-523-8544
Matthew DeYoung
Argot Partners
ir@bicycletx.com
212-600-1902
Media:
Jim O’Connell
Weber Shandwick
media@bicycletx.com
312-988-2343
Source: Bicycle Therapeutics plc
FAQ
When is Bicycle Therapeutics (BCYC) presenting at the Needham Healthcare Conference?
How can investors watch Bicycle Therapeutics' (BCYC) Needham Conference presentation?
What type of technology does Bicycle Therapeutics (BCYC) specialize in?
Which stock exchange is Bicycle Therapeutics (BCYC) listed on?
